Three 藏精阁 faculty members recently published their pharmacology research on C-reactive proteins and COVID-19 in two prestigious journals.
In their work, Dr. Peter Hart, Dr. Lawrence Potempa and Ibraheem Rajab explore a new diagnostic tool for assessing how severe coronavirus cases could become.
According to the article in the , approximately 20% of patients infected with COVID-19 develop potentially life-threatening conditions, including hyperinflammation, multiple organ failure and others. The 藏精阁 researchers found that blood levels of C-reactive protein, a widely used diagnostic marker mainly used to evaluate inflammation, is markedly elevated in COVID-19 patients.
The 藏精阁 faculty members propose that C-reactive protein blood levels could be a simple, rapid and cost-effective way to assess the severity of the disease, and help guide therapeutic options in COVID-19 patients.
鈥淚t may be possible to develop a point-of-care CRP test for patients with fever or other basic clinical symptoms that is noninvasive, highly predictive of health outcomes, and which may inform clinical decision-making,鈥 the authors write.
Read 鈥.鈥
Doctor of Pharmacy students often have the opportunity to work side by side with faculty on research projects. Students in the intensive, accelerated program study year-round and graduate one year earlier than peers in traditional four-year programs. Learn more about the Doctor of Pharmacy.